Advancing novel product candidates for cardiac disease as well as inborn errors of metabolism
We are advancing a clinical stage pipeline of novel product candidates in two key areas of energy metabolism: cardiovascular disease and inborn errors of metabolism.
Our lead program, ninerafaxstat, is currently in Phase 2 clinical development for conditions of oxygen deprivation in the heart. The initial indications we are targeting with ninerafaxstat are non-obstructive hypertrophic cardiomyopathy, heart failure and stable angina. Our additional product candidate, IMB-203 is designed to address the energy deficiency in patients with rare genetic mutations in mitochondrial metabolism, including those with propionic acidemia and other inborn errors of metabolism.